Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

表儿茶素的早期临床前和初步临床研究

• 批准号: 8719394
• 负责人: Robert Roy Henry
• 金额: $ 64.27万
• 依托单位: VETERANS MEDICAL RESEARCH FDN/SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8719394
• 关键词: Animals; Award; Blood; Blood Pressure; Blood specimen; Canis familiaris; Clinical; Clinical Chemistry; Clinical Research; Consultations; Contract Services; Data; Dose; Drug Kinetics; Electrocardiogram; Funding; Future; Glucose; Goals; Grant; Human; Inflammation; Insulin; Intervention; Investigational Drugs; Investigational New Drug Application; Lipids; Longitudinal Studies; Measures; Mitochondria; New Drug Approvals; Pharmaceutical Preparations; Pharmacodynamics; Phase; Regulation; Research; Rodent; Safety; Sampling; Scientist; Serum; Structure; Testing; Toxicology; Urine; Work; base; cytokine; epicatechin; human subject; macrophage; metabolomics; phase 1 study; pre-clinical; primary outcome; secondary outcome

The major objective of this award is to fund early phase pre-clinical work and initial clinical research in support of a planned future P01 application using an epicatechin based intervention in human subjects. A research plan has been developed whose ultimate goal is the granting of an Investigational New Drug (IND) approval by the Federal Drug Administration (FDA). An IND approval would allow the implementation of clinical studies using (+/-)-epicatechin (i.e., epicatechin racemate). The plan is structured around 6 major goals (aims) as follows: Aim 1. Complete a pre-IND consultation package to be submitted to the FDA. Participating scientists will prepare a pre-IND application package for consultation with the FDA to ascertain the information and data required for a future IND submission and approval. Aim 2. Pursue pharmacokinetic (PK) studies in rodents and/or dogs using (+/-)-epicatechin. Future dose optimization studies in humans may require initial studies in animals to identify a dose range deemed likely to be effective for the racemic epicatechin mixture. Aim 3. Employ outside contracting services to pursue toxicology studies in rodents and/or dogs using (+/-)-epicatechin. A 28-day toxicology study in rodents and/or dogs will be implemented to evaluate the safety of (+/-)-epicatechin, data that may be essential for its subsequent use in humans. Aim 4. Based upon the above collected information and results, submit an IND application to the FDA in pursuit of phase I studies. The research team will collect all relevant information and results for the submission of an IND application to the FDA to implement phase I studies in humans. Aim 5. Phase I studies: Perform single and multi-dose PK and pharmacodynamic (PD) analysis of (+/-)-epicatechin in human subjects to determine a safe dosing range. For one day studies, human subjects will be given (+/-)-epicatechin (one of up to six incremental doses) and blood sampled serially. For 7 day studies, repeated daily dosing with (+/-)-epicatechin will take place and blood also sampled serially. Primary outcomes will be safety measures (e.g., electrocardiogram, blood pressure, clinical chemistry) and concentrations of epicatechin in blood and urine. Secondary outcomes will be lipids, glucose and insulin concentrations, and markers of systemic inflammation. Aim 5 includes contingency plans (sub aims A and B) in case animal studies are not required by the FDA. Aim 5A will use blood samples collected to ascertain macrophage polarity and regulation of cytokine secretion. Aim 5B will use serum samples collected to perform metabolomics profiling and test for evidence of altered mitochondrial function. Aim 6. Based upon all of the above collected information and Phase I results (Aim 5), submit an IND application to the FDA in pursuit of long-term clinical studies in humans. The proposed plan will ultimately allow the research team to gather critical pre-clinical and clinical information deemed likely to be required by the FDA in granting approval for longer-term studies in human subjects using the epicatechin racemate.

该奖项的主要目的是资助早期临床前工作和初步临床研究，以支持计划中的未来P01应用，使用基于表儿茶素的干预人类受试者。已经制定了一项研究计划，其最终目标是获得联邦药品监督管理局（FDA）的研究性新药（IND）批准。IND批准将允许使用（+/-）-表儿茶素（即，表儿茶素总皂苷）。该计划围绕以下6个主要目标（目的）展开：目的1。完成提交给FDA的IND前咨询包。参与的科学家将准备一份IND前申请包，以与FDA协商，确定未来IND提交和批准所需的信息和数据。目标二。在啮齿类动物和/或犬中使用（+/-）-表儿茶素进行药代动力学（PK）研究。未来的人体剂量优化研究可能需要在动物中进行初步研究，以确定外消旋表儿茶素混合物可能有效的剂量范围。目标3.雇用外部承包服务，使用（+/-）-表儿茶素在啮齿动物和/或犬中进行毒理学研究。将在啮齿动物和/或犬中进行为期28天的毒理学研究，以评价（+/-）-表儿茶素的安全性，这些数据可能对其随后在人体中的使用至关重要。目标4。根据上述收集的信息和结果，向FDA提交IND申请，以进行I期研究。研究团队将收集所有相关信息和结果，以便向FDA提交IND申请，以实施人体I期研究。目标5。I期研究：在人类受试者中进行（+/-）-表儿茶素的单次和多次给药PK和药效学（PD）分析，以确定安全剂量范围。对于一天的研究，将给予人类受试者（+/-）-表儿茶素（最多六个递增剂量中的一个）并连续采集血液样本。对于7天的研究，将进行（+/-）-表儿茶素的重复每日给药，并且还连续采集血液。主要结局将是安全性指标（例如，心电图、血压、临床化学）以及血液和尿液中表儿茶素的浓度。次要结果将是脂质、葡萄糖和胰岛素浓度以及全身炎症标志物。目标5包括应急计划（子目标A和B），以防FDA不要求进行动物研究。目的5A将使用收集的血液样品来确定巨噬细胞极性和细胞因子分泌的调节。目的5 B将使用收集的血清样本进行代谢组学分析，并测试线粒体功能改变的证据。目标6。根据上述收集的所有信息和I期结果（目标5），向FDA提交IND申请，以进行人体长期临床研究。拟议的计划最终将允许研究小组收集FDA在批准使用表儿茶素rachloride进行人类受试者长期研究时可能需要的关键临床前和临床信息。